Clinical Trial Update: Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes [Phase 4]

View source ↗

Summary

Phase 4 study indicates that genetic differences influence how much weight loss is achieved with sibutramine (Meridia) in individuals with obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Meridia (sibutramine)

Snippet

Sponsor: Mayo Clinic | Conditions: Obesity | Phase 4 | Status: COMPLETED